Details for Patent: 8,796,276
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,796,276 protect, and when does it expire?
Patent 8,796,276 protects ARISTADA and ARISTADA INITIO KIT and is included in two NDAs.
This patent has forty-three patent family members in twenty countries.
Summary for Patent: 8,796,276
Title: | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Abstract: | Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed. ##STR00001## |
Inventor(s): | Remenar; Julius F. (Framingham, MA), Blumberg; Laura Cook (Lincoln, MA), Zeidan; Tarek A. (Watertown, MA) |
Assignee: | Alkermes Pharma Ireland Limited (Dublin, IE) |
Application Number: | 13/607,066 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,796,276
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-001 | Oct 5, 2015 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | TREATMENT OF SCHIZOPHRENIA | See Plans and Pricing | ||||
Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-002 | Oct 5, 2015 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | TREATMENT OF SCHIZOPHRENIA | See Plans and Pricing | ||||
Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-003 | Oct 5, 2015 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | TREATMENT OF SCHIZOPHRENIA | See Plans and Pricing | ||||
Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-004 | Jun 5, 2017 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | TREATMENT OF SCHIZOPHRENIA | See Plans and Pricing | ||||
Alkermes Inc | ARISTADA INITIO KIT | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 209830-001 | Jun 29, 2018 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | TREATMENT OF SCHIZOPHRENIA | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,796,276
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 077239 | See Plans and Pricing | |||
Argentina | 109699 | See Plans and Pricing | |||
Australia | 2010266018 | See Plans and Pricing | |||
Australia | 2010266040 | See Plans and Pricing | |||
Canada | 2766033 | See Plans and Pricing | |||
Canada | 2766088 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |